FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2790615713> ?p ?o ?g. }

• W2790615713 abstract "Introduction. Male breast cancer (male BC) is a rare disease for which disease management is extrapolated from females. IMBC, an international consortium, which previously reported on clinico-pathological aspects, now reports on molecular subgroups revealed by RNA sequencing and their relation to patient outcome. Methods. Tumor samples from the retrospective MALE BC registry diagnosed between 1990-2010 and with pathology and outcome data (relapse-free- (RFS) and overall survival (OS)) were included (n=699). To allow the discovery of prognostic features, we selected, stratified for known risk factors (TN stage, grade, age at diagnose and adjuvant endocrine treatment), from the cohort 152 cases with poor (RFS 7yrs) evenly distributed. Here, we report RNA sequencing results of the first 73 cases, 38 with poor and 35 with good outcome. RNA sequencing reads were used to generate gene expression values and to report transcripts carrying driver mutations. Unsupervised clustering identified subgroups and within subgroups differentially expressed genes were identified. The reported prognostic male BC subgroups M1 and M2 (Johansson BCR 2012(14):R31) were also annotated. All identified subgroups were related to outcome using logistic regression (p-value using Wald test). Results. Unsupervised clustering revealed 2 main subgroups of which group 1 was enriched for expression of ER target genes, WNT3 and genes from amplicons known for female BC, e.g. 19p13 (CCNE1), 8q24 (MYC), and 11q13 (CCND1). The biology of the smaller group 2 was less defined but TGFβ2 expression was high as were various kallikreins (KLK) including interestingly KLK3 (prostate specific antigen). Other known amplified regions [(8p11 (FGFR1), 20q13 (ZNF217) and 12q15 (MDM2)] and mutated transcripts [PIK3CA (H1047R/L/Q; E542K, E545K, N345K; 16% of cases), TP53 and SF3B1 (K700E) (2% of cases)] were identified. Profound tumor infiltrate gene expression was present in 5% of cases and one third of cases expressed proliferation markers. Except for TP53, none of these latter characteristics were unevenly distributed among the 2 main subgroups. ER and AR were highly correlated, particularly in group 1. The two main groups could be further subdivided. Group 1 comprised 3 subgroups of which subgroup 1a expressed TFF1/3 and NAT1, well-known ER targets, while subgroups 1b and 1c expressed other ER targets,respectively BEX1 and PITX1. HOXC cluster expression differentiated subgroup 1b from 1a and 1c. None of these intrinsic subgroups were, however, related to RFS. The previously reported M2 subgroup, which largely segregated with subclusters 1a and 1b, was associated with a better RFS than the M1 subgroup (OR=2.9; 95%CI 1.1-7.5; p-value=0.03). Conclusions. 1) Intrinsic subtypes of male BC were revealed and their subgrouping is defined by ER associated subsets of genes. 2) The association of the reported M2 subgroup of male BC with longer RFS was validated; 3) Currently identified biological characteristics of male BC may improve future treatments. The full report on 152 cases including a comparison to female BC will be presented at the conference. This research was funded by Breast Cancer Research Foundation Citation Format: Martens JWM, Sieuwerts A, Ponchet C, Smid M, de Weerd V, Slaets L, Piper T, van Deurzen CHM, Schroder CP, Stangle C, Kloosterman W, van Leeuwen-Stok E, Nilsson C, Vermeij J, Peeters S, Goulioti T, Nowaczyk M, Aebi S, Rubio IT, Kelly C, Bayani J, Porter P, Murray M, Hudis C, Middleton L, Korde L, Ruddy K, Winer E, Bogler O, van den Weyngaert D, dal Lago L, Fraser J, Benstead K, van Asperen C, Linderholm B, Hedenfalk I, Tryfonidis K, Giordano S, Bartlett J, Cardoso F. Molecular subtyping of male breast cancer by the International male breast cancer program (IMBC): EORTC 10085/TBCRC 0-29/BIG 2-07/NABCG/BOOG 2009-04 [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr PD7-12." @default.
• W2790615713 created "2018-03-29" @default.
• W2790615713 creator A5000139645 @default.
• W2790615713 creator A5001697773 @default.
• W2790615713 creator A5003934165 @default.
• W2790615713 creator A5005004931 @default.
• W2790615713 creator A5007307440 @default.
• W2790615713 creator A5008290921 @default.
• W2790615713 creator A5015096134 @default.
• W2790615713 creator A5016282606 @default.
• W2790615713 creator A5016466918 @default.
• W2790615713 creator A5017731471 @default.
• W2790615713 creator A5018596516 @default.
• W2790615713 creator A5022702371 @default.
• W2790615713 creator A5022764209 @default.
• W2790615713 creator A5023200887 @default.
• W2790615713 creator A5029260009 @default.
• W2790615713 creator A5029590188 @default.
• W2790615713 creator A5030976537 @default.
• W2790615713 creator A5037198503 @default.
• W2790615713 creator A5037339432 @default.
• W2790615713 creator A5040688902 @default.
• W2790615713 creator A5041335829 @default.
• W2790615713 creator A5043421992 @default.
• W2790615713 creator A5051792739 @default.
• W2790615713 creator A5053299342 @default.
• W2790615713 creator A5054320718 @default.
• W2790615713 creator A5054574944 @default.
• W2790615713 creator A5056381732 @default.
• W2790615713 creator A5060320368 @default.
• W2790615713 creator A5062106369 @default.
• W2790615713 creator A5063501932 @default.
• W2790615713 creator A5063639007 @default.
• W2790615713 creator A5066273676 @default.
• W2790615713 creator A5070245248 @default.
• W2790615713 creator A5071991781 @default.
• W2790615713 creator A5075924189 @default.
• W2790615713 creator A5076556096 @default.
• W2790615713 creator A5077029227 @default.
• W2790615713 creator A5080137262 @default.
• W2790615713 creator A5083013954 @default.
• W2790615713 creator A5091846363 @default.
• W2790615713 date "2018-02-14" @default.
• W2790615713 modified "2023-09-26" @default.
• W2790615713 title "Abstract PD7-12: Molecular subtyping of male breast cancer by the International male breast cancer program (IMBC): EORTC 10085/TBCRC 0-29/BIG 2-07/NABCG/BOOG 2009-04" @default.
• W2790615713 doi "https://doi.org/10.1158/1538-7445.sabcs17-pd7-12" @default.
• W2790615713 hasPublicationYear "2018" @default.
• W2790615713 type Work @default.
• W2790615713 sameAs 2790615713 @default.
• W2790615713 citedByCount "0" @default.
• W2790615713 crossrefType "proceedings-article" @default.
• W2790615713 hasAuthorship W2790615713A5000139645 @default.
• W2790615713 hasAuthorship W2790615713A5001697773 @default.
• W2790615713 hasAuthorship W2790615713A5003934165 @default.
• W2790615713 hasAuthorship W2790615713A5005004931 @default.
• W2790615713 hasAuthorship W2790615713A5007307440 @default.
• W2790615713 hasAuthorship W2790615713A5008290921 @default.
• W2790615713 hasAuthorship W2790615713A5015096134 @default.
• W2790615713 hasAuthorship W2790615713A5016282606 @default.
• W2790615713 hasAuthorship W2790615713A5016466918 @default.
• W2790615713 hasAuthorship W2790615713A5017731471 @default.
• W2790615713 hasAuthorship W2790615713A5018596516 @default.
• W2790615713 hasAuthorship W2790615713A5022702371 @default.
• W2790615713 hasAuthorship W2790615713A5022764209 @default.
• W2790615713 hasAuthorship W2790615713A5023200887 @default.
• W2790615713 hasAuthorship W2790615713A5029260009 @default.
• W2790615713 hasAuthorship W2790615713A5029590188 @default.
• W2790615713 hasAuthorship W2790615713A5030976537 @default.
• W2790615713 hasAuthorship W2790615713A5037198503 @default.
• W2790615713 hasAuthorship W2790615713A5037339432 @default.
• W2790615713 hasAuthorship W2790615713A5040688902 @default.
• W2790615713 hasAuthorship W2790615713A5041335829 @default.
• W2790615713 hasAuthorship W2790615713A5043421992 @default.
• W2790615713 hasAuthorship W2790615713A5051792739 @default.
• W2790615713 hasAuthorship W2790615713A5053299342 @default.
• W2790615713 hasAuthorship W2790615713A5054320718 @default.
• W2790615713 hasAuthorship W2790615713A5054574944 @default.
• W2790615713 hasAuthorship W2790615713A5056381732 @default.
• W2790615713 hasAuthorship W2790615713A5060320368 @default.
• W2790615713 hasAuthorship W2790615713A5062106369 @default.
• W2790615713 hasAuthorship W2790615713A5063501932 @default.
• W2790615713 hasAuthorship W2790615713A5063639007 @default.
• W2790615713 hasAuthorship W2790615713A5066273676 @default.
• W2790615713 hasAuthorship W2790615713A5070245248 @default.
• W2790615713 hasAuthorship W2790615713A5071991781 @default.
• W2790615713 hasAuthorship W2790615713A5075924189 @default.
• W2790615713 hasAuthorship W2790615713A5076556096 @default.
• W2790615713 hasAuthorship W2790615713A5077029227 @default.
• W2790615713 hasAuthorship W2790615713A5080137262 @default.
• W2790615713 hasAuthorship W2790615713A5083013954 @default.
• W2790615713 hasAuthorship W2790615713A5091846363 @default.
• W2790615713 hasConcept C104317684 @default.
• W2790615713 hasConcept C121608353 @default.
• W2790615713 hasConcept C126322002 @default.
• W2790615713 hasConcept C143998085 @default.
• W2790615713 hasConcept C2777396416 @default.
• W2790615713 hasConcept C2780192828 @default.
• W2790615713 hasConcept C49105822 @default.
• W2790615713 hasConcept C530470458 @default.
• W2790615713 hasConcept C54355233 @default.

• next